Gastric Cancer: 早期和晚期印戒细胞腺癌之间的临床病理差异

2019-10-21 不详 MedSci原创

印戒细胞腺癌是基于WHO分类的组织学分类。这种特定的组织学类型的存在与较差的病理学表现有关。根治性手术后印戒细胞腺癌患者的预后目前仍具有争议,本项研究旨在研究二者之间的联系。

背景
印戒细胞腺癌是基于WHO分类的组织学分类。这种特定的组织学类型的存在与较差的病理学表现有关。根治性手术后印戒细胞腺癌患者的预后目前仍具有争议,本项研究旨在研究二者之间的联系。

方法
研究人员从1988年1月至2012年12月间收集共297例接受了根治性癌切除术的患者,包括819例早期癌和2152例晚期胃癌患者。其中,早期胃癌患者有185例印戒细胞腺癌,晚期胃癌患者有570例。

结果
图章环细胞腺癌的总发病率为25.4%。患有印戒细胞癌和非印戒细胞腺癌的早期胃癌患者的5年总生存率分别为90.7和83.2%(P= 0.001)。早期患有印戒环细胞腺癌和非印戒环细胞腺癌的胃癌患者的5年生存率分别为87.4和81.6%(P= 0.003)。晚期胃癌伴印戒细胞腺癌和非印戒细胞腺癌的5年总生存率分别为32.1%和37.9%(P= 0.041)。晚期胃癌伴印戒细胞腺癌和非印戒细胞腺癌的5年无病生存率分别为28.6%和35.2%(P= 0.037)。印戒细胞腺癌是晚期胃癌总体生存的独立预测因子(P= 0.017)。

结论
在早期和晚期胃癌中,印戒细胞腺癌的临床特征和预后不同。印戒细胞腺癌是根治性切除术后晚期胃癌的不良预后因素。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797476, encodeId=6c231e974760f, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 09 23:39:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893652, encodeId=086418936527e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Jan 13 23:39:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712147, encodeId=665a1e1214729, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Jul 09 21:39:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072746, encodeId=458020e27466d, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Dec 18 21:39:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797476, encodeId=6c231e974760f, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 09 23:39:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893652, encodeId=086418936527e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Jan 13 23:39:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712147, encodeId=665a1e1214729, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Jul 09 21:39:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072746, encodeId=458020e27466d, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Dec 18 21:39:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
    2020-01-13 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797476, encodeId=6c231e974760f, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 09 23:39:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893652, encodeId=086418936527e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Jan 13 23:39:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712147, encodeId=665a1e1214729, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Jul 09 21:39:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072746, encodeId=458020e27466d, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Dec 18 21:39:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797476, encodeId=6c231e974760f, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 09 23:39:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893652, encodeId=086418936527e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Jan 13 23:39:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712147, encodeId=665a1e1214729, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Jul 09 21:39:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072746, encodeId=458020e27466d, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Dec 18 21:39:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
    2019-12-18 许安

相关资讯

Gastric Cancer: 胃癌切除术后非酒精性脂肪肝的危险因素分析

非酒精性脂肪肝疾病(NAFLD)是指除酒精性肝损伤以外的其他原因引起的肝脂肪变性,通常发生在胃肠道手术(如胰十二指肠切除术和胃切除术)之后。本研究旨在确定胃癌胃切除术后NAFLD的危险因素。

Gastric Cancer:血液和骨髓中角蛋白阳性CD44 +肿瘤细胞与胃癌患者预后不良相关

外周血中循环肿瘤细胞(CTC)和骨髓中弥散性肿瘤细胞(DTC)的表型异质性是临床决策的重要依据。本项研究探究了这些细胞的两个不同亚群在胃癌(GC)中的意义。

Gastric Cancer: 根治性胃癌切除术后30天医院再次入院的危险因素分析

作为医疗质量衡量标准的医院再入院率越来越受到关注。加速康复的引入缩短了住院时间,却没有增加术后并发症和再次入院的风险。本研究的目的是评估胃癌切除术后出院后30天内再次入院的危险因素。

Gastric Cancer: 术前改良全身炎症评分胃癌患者术后预后的预测作用

基于术前血清白蛋白(Alb)水平和淋巴细胞与单核细胞比率(LMR)的全身炎症评分(SIS)已被证明是某些肿瘤的新型预后评分模型。本项研究旨在探究SIS是否可在胃癌(GC)患者中的起到预测作用。

Gastric cancer: 术前多西他赛联合顺铂加S-1治疗广泛淋巴结转移的胃癌的长期预后分析

在日本,术前用顺铂加S-1(CS)进行化疗,然后行D2加上主动脉旁淋巴结清扫术(PAN)进行胃切除术是晚期胃癌伴大淋巴结(BN)和/或PAN转移的标准治疗方法。本项研究则对多西他赛添加到CS(DCS)中以进一步改善长期疗效,并探究的其长期的预后效果。

Gastric Cancer:单纯手术是否足以治疗具有广泛淋巴结转移的T1型胃癌

单独手术治疗是否足以治疗病理分期T1N2M0(IIA期),T1N3a / bM0(IIB / IIIB期)和T3N0M0(IIA期)胃癌的患者目前仍不清楚。本项研究旨在探究二者之间的关系。